Results 61 to 70 of about 38,609 (257)

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Systematic Review of Neovascular Age-Related Macular Degeneration Disease Activity Criteria Use to Shorten, Maintain or Extend Treatment Intervals with Anti-VEGF in Clinical Trials: Implications for Clinical Practice

Ophthalmology and Therapy, 2023
Introduction Clinical trials in neovascular age-related macular degeneration (nAMD) using anti-vascular endothelial growth factor (ant-VEGF) injections use disease activity (DA) criteria to shorten, maintain or increase the interval between injections ...
Praveen J. Patel, Pablo Villavicencio, Daren Hanumunthadu   +2 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients

CPT: Pharmacometrics & Systems Pharmacology, 2023
Atezolizumab is an anti‐PDL1 approved for treating lung cancer. A threshold of 6 μg/mL in plasma has been associated with target engagement. The extent to which patients could be overexposed with the standard 1200 mg q3w dosing remains unknown.
Sophie Marolleau, Alice Mogenet, Clara Boeri, Mourad Hamimed, Joseph Ciccolini, Laurent Greillier   +5 more
doaj   +1 more source

Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach

Antibiotics, 2021
Beta-lactam antibiotics are often the backbone of treatment for Gram-negative infections in the critically ill. Beta-lactams exhibit time-dependent killing, and their efficacy depends on the percentage of dosing interval that the concentration remains ...
Kelly L. Maguigan, Mohammad H. Al-Shaer, Charles A. Peloquin   +2 more
doaj   +1 more source

Eight years' experience of an extended-interval dosing protocol for gentamicin in neonates

, 2009
Background: Dosing of gentamicin in neonates in Christchurch has been carried out since 2000 using a locally developed extended-interval dosing protocol. All dosing data have been recorded in a database.
Robertshawe, B., E. J. Begg, C. M. J. Kirkpatrick, Begg, E. J., B. Darlow, Vella-Brincat, J. W. A., Kirkpatrick, Carl, Kirkpatrick, Carl M.J., B. Robertshawe, McMurtrie, M. J., McMurtrie, Mark, Begg, Evan, M. J. McMurtrie, J. W. A. Vella-Brincat, Vella-Brincat, Jane, Darlow, B., Robertshawe, Barbara, Darlow, Brian   +17 more
core   +1 more source

sj-docx-1-msj-10.1177_13524585231208311 – Supplemental material for Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity

, 2023
Supplemental material, sj-docx-1-msj-10.1177_13524585231208311 for Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity by Nicole Bou Rjeily, Kathryn C Fitzgerald ...
Nicole Bou Rjeily (17372684), Kathryn C Fitzgerald (6338204), Ellen M Mowry (6338231)   +2 more
core   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Administration of Higher Doses of Amikacin in Early Stages of Sepsis in Critically Ill Patients

Acta Medica Iranica, 2014
High-dose extended-interval dosage (HDED) regimen of aminoglycosides is now considered as the standard dosage strategy in sepsis. Although safety and efficacy of this dosing regimen is well studied, but new experiments show increased the risk of ...
Farhad Najmeddin, Arezoo Ahmadi, Laleh Mahmoudi, Kourosh Sadeghi, Hossein Khalili, Alireza Ahmadvand, Atabak Najafi, Mojtaba Mojtahedzadeh   +7 more
doaj  

Case Report: Extending dosing intervals of biologics in adults severe asthma: a case series

Frontiers in Allergy
BackgroundBiological therapies have improved the control of severe asthma. However, biological therapies are expensive. Therefore, the cost-effective use of these medications after achieving improved disease control warrants consideration.MethodsThis ...
Tomoya Harada, Miyu Nishigami, Hiroyuki Tanaka, Hiroyuki Tanaka, Genki Inui, Hiroki Ishikawa, Hiroki Kohno, Yoshihiro Funaki, Tomohiro Sakamoto, Miki Takata, Ryota Okazaki, Masato Morita, Shin Kitatani, Akira Yamasaki   +13 more
doaj   +1 more source